Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Potency of levothyroxine products.

S S Stoffer, W E Szpunar

    JAMA
    |February 3, 1984
    PubMed
    Summary

    Levothyroxine potency has increased to 100% due to a switch to high-pressure liquid chromatography (HPLC) manufacturing. This change has led to improved thyroid function test results in patients, with higher free thyroxine index levels observed.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer.

    American journal of human genetics·1997
    Same author

    Induction of adrenal suppression by megestrol acetate.

    Annals of internal medicine·1996
    Same author

    Do specialists screen for breast cancer?

    JAMA·1995
    Same author

    Relation of osteopenia to glucocorticoid replacement therapy in Addison disease.

    Annals of internal medicine·1994
    Same author

    Addison's disease. How to improve patients' quality of life.

    Postgraduate medicine·1993
    Same author

    Technetium-99m-sestamibi uptake by recurrent Hurthle cell carcinoma of the thyroid.

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine·1992

    Area of Science:

    • Endocrinology
    • Pharmaceutical Science

    Background:

    • Levothyroxine is a critical medication for thyroid hormone replacement therapy.
    • Previous levothyroxine products exhibited variable potency, with some showing only 78% of expected levels.
    • Manufacturing processes for pharmaceuticals are subject to change and require ongoing monitoring.

    Purpose of the Study:

    • To assess the impact of a manufacturing change in levothyroxine production on product potency.
    • To evaluate the clinical effects of the updated levothyroxine product on patient thyroid function.
    • To alert physicians to potential shifts in levothyroxine product quality.

    Main Methods:

    • Utilized high-pressure liquid chromatography (HPLC) for product potency monitoring.
    • Employed radioimmunoassay (RIA) in-house laboratory testing to verify levothyroxine potency.
    • Analyzed patient serum free thyroxine index (FTI) and thyroid-stimulating hormone (TSH) levels.

    Main Results:

    • The brand-name levothyroxine product now demonstrates 100% of expected potency via HPLC and RIA.
    • Patients using the updated levothyroxine product showed a higher mean serum FTI.
    • An increase in elevated serum FTI levels and a decrease in elevated serum TSH levels were noted this year.

    Conclusions:

    • The transition to HPLC manufacturing has resulted in a more potent and consistent levothyroxine product.
    • Physicians should monitor thyroid function closely as levothyroxine manufacturers adopt new methods.
    • The updated levothyroxine products are expected to offer improved consistency and shelf-life reliability.

    Related Experiment Videos